NASDAQ:MDVN - Medivation Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $81.44 0.00 (0.00 %) (As of 09/25/2018 02:42 AM ET)Previous Close$81.44Today's Range$81.44 - $81.4452-Week Range$26.41 - $81.48VolumeN/AAverage Volume3.55 million shsMarket Capitalization$13.52 billionP/E RatioN/ADividend YieldN/ABeta0.6 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463. Receive MDVN News and Ratings via Email Sign-up to receive the latest news and ratings for MDVN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A SymbolNASDAQ:MDVN CUSIP58501N10 Webwww.medivation.com Phone+1-415-5433470 Debt Debt-to-Equity Ratio0.03 Current Ratio4.32 Quick Ratio4.32 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins-195.92% Return on Equity-225.98% Return on Assets-108.55% Miscellaneous Employees628 Outstanding Shares165,010,000Market Cap$13.52 billion Medivation (NASDAQ:MDVN) Frequently Asked Questions What is Medivation's stock symbol? Medivation trades on the NASDAQ under the ticker symbol "MDVN." How were Medivation's earnings last quarter? Medivation Inc (NASDAQ:MDVN) released its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.27 by $0.02. The biopharmaceutical company earned $206 million during the quarter, compared to analysts' expectations of $214.52 million. Medivation had a negative net margin of 195.92% and a negative return on equity of 225.98%. Medivation's revenue for the quarter was up 17.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.58 EPS. View Medivation's Earnings History. How do I buy shares of Medivation? Shares of MDVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Medivation's stock price today? One share of MDVN stock can currently be purchased for approximately $81.44. How big of a company is Medivation? Medivation has a market capitalization of $13.52 billion. Medivation employs 628 workers across the globe. What is Medivation's official website? The official website for Medivation is http://www.medivation.com/. How can I contact Medivation? Medivation's mailing address is 525 Market St Fl 36, SAN FRANCISCO, CA 94105-2747, United States. The biopharmaceutical company can be reached via phone at +1-415-5433470. MarketBeat Community Rating for Medivation (NASDAQ MDVN)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 659 (Vote Outperform)Underperform Votes: 402 (Vote Underperform)Total Votes: 1,061MarketBeat's community ratings are surveys of what our community members think about Medivation and other stocks. Vote "Outperform" if you believe MDVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDVN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/25/2018 by MarketBeat.com StaffFeatured Article: What is a Stop Order?